Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BT4P
|
||||
| Former ID |
DIB014605
|
||||
| Drug Name |
TDI-0060
|
||||
| Indication | Motor neurone disease [ICD9: 335.2; ICD10:G12.2] | Investigative | [1] | ||
| Company |
ALS Therapy Development Foundation Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Superoxide dismutase [Cu-Zn] | Target Info | Modulator | [1] | |
| BioCyc Pathway | Reactive oxygen species degradation | ||||
| KEGG Pathway | Peroxisome | ||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington's disease | |||||
| Prion diseases | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | ||||
| FOXA1 transcription factor network | |||||
| PathWhiz Pathway | Degradation of Superoxides | ||||
| Reactome | Platelet degranulation | ||||
| Detoxification of Reactive Oxygen Species | |||||
| WikiPathways | Oxidative Stress | ||||
| Copper homeostasis | |||||
| Detoxification of Reactive Oxygen Species | |||||
| Nifedipine Activity | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Dopamine metabolism | |||||
| AGE/RAGE pathway | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.